Immuneering Corporation
NASDAQ:IMRXBiotechnology
-$0.01 today
- Market cap
- $224.08M
- Beta
- 0.38
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.24
Volume 1.25M
Average 1.38M
Returns on capital
Immuneering Corporation management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-25.6%
avg -15.1%
ROIC
-26.7%
avg -55.4%
ROA
-24.2%
avg -50.4%
Analysis
ROA is currently the strongest return metric at -24.2% versus its period average of -50.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Benjamin J. Zeskind | Co-Founder, President, Chief Executive Officer & Director | USD 1.08M | 43 | 2.32M | 6.38% |
Brett Hall | Chief Scientific Officer | USD 999.75K | 57 | — | — |
Michael D. Bookman | Chief Legal Officer & Secretary | USD 757.56K | 39 | — | — |
Robert J. Carpenter | Co-Founder & Chair Emeritus | USD 45K | 80 | 33.35K | 0.09% |
Jyoti Joshi | Director of Quality Systems & Compliance | — | — | — | — |
Mallory Morales | Senior VP of Finance, Chief Accounting Officer & Assistant Treasurer | — | 43 | 140.00K | 0.39% |
Paula George | Senior Director of Accounting & Operations and Assistant Corporate Controller | — | — | — | — |
Andrew W. Gengos | CFO & Treasurer | — | 62 | — | — |
David Caouette | Vice President of Corporate Communications | — | — | — | — |
Leah R. Neufeld | Chief People Officer | — | 54 | 29.60K | 0.08% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 23, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
7
$270,335.99
Sells
0
$0.00
Net Transaction Value
+$270,335.99
Net buying
Most Active
Hall Brett Matthew
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jun 23, 26Jun 23, 2026 | Zeskind Benjamin J. Direct | Buy | $10.9K$10,948.08 |
| Jun 15, 26Jun 15, 2026 | Hall Brett Matthew Direct | Buy | $25K$25,045.25 |
| Jan 16, 26Jan 16, 2026 | Brakewood Harold Eugene Direct | Buy | $25K$24,990.00 |
| Jan 15, 26Jan 15, 2026 | Schall Thomas J. Direct | Buy | $101K$101,041.02 |
| Jan 15, 26Jan 15, 2026 | Hall Brett Matthew Direct | Buy | $10.5K$10,501.86 |
| Jan 13, 26Jan 13, 2026 | Neufeld Leah R Direct | Buy | $10.9K$10,905.78 |
| Jan 12, 26Jan 12, 2026 | Feinberg Peter Indirect | Buy | $86.9K$86,904.00 |
Summary
Insiders reported 7 buys worth $270,335.99 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $270,335.99. Hall Brett Matthew was the most active insider with 2 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Immuneering Corporation compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about IMRX's management, answered from reported figures.
Who manages IMRX?
Immuneering Corporation (IMRX) lists 10 active executives. The top listed executive is Jyoti Joshi, Director of Quality Systems & Compliance.
Are IMRX insiders buying or selling?
Recent insider activity shows net buying of $24.89M.
Continue the stock analysis
Jump to another research area for this company.